MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jiac.2024.09.020

Медицинская библиотека · Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2024

The effect of baricitinib and corticosteroid compared to that of corticosteroid monotherapy in severely and critically ill patients with COVID-19: A Japanese multicenter inpatient database study.

Mizuno Tomoki, Suzuki Jun, Takahashi Shota, Imai Haruka, Itagaki Hideya, Yoshida Makiko, Endo Shiro

СтатьяМногоцентровое исследованиеСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Systemic baricitinib and corticosteroids play important roles in treating severely and critically ill patients with coronavirus disease 2019 (COVID-19). However, the efficacy of the combination of baricitinib and corticosteroids compared to that of corticosteroid monotherapy in severely and critically ill hospitalized patients with COVID-19 remains unclear.

METHODS

We analyzed severely and critically ill hospitalized patients with COVID-19 aged >18 years between January 1, 2020 and May 31, 2023, using a Japanese multicenter inpatient database. We performed propensity score matching to analyze the effect of the combination of baricitinib and corticosteroids within 2 days of hospital admission (combination group) on the 28-day and in-hospital mortality rates compared with those of corticosteroid monotherapy within 2 days of hospital admission (control group). Sensitivity analysis was performed using inverse probability weighting analysis and the generalized estimating equation method.

RESULTS

The eligible patients (n = 7433) were divided into a combination (n = 679) and a control group (n = 6754). One-to-four propensity score matching analyses included 566 combination and 2264 control group patients. There was no significant difference in 28-day (8.5 % vs. 8.8 %; risk difference, -0.3 % [95 % confidence interval, -2.9 to 2.3]) or in-hospital (11 % vs. 10 %; risk difference, 1.0 [-1.9 to 3.9]) mortality rates between 2 groups. The sensitivity analysis showed similar outcomes.

CONCLUSION

This observational study, using a Japanese multicenter inpatient database, found that the combination of baricitinib and corticosteroid therapy did not improve the 28-day or in-hospital mortality rates in severely and critically ill patients with COVID-19 compared to corticosteroid monotherapy.

Для цитирования: Mizuno Tomoki, Suzuki Jun, Takahashi Shota, Imai Haruka, Itagaki Hideya, Yoshida Makiko, Endo Shiro. The effect of baricitinib and corticosteroid compared to that of corticosteroid monotherapy in severely and critically ill patients with COVID-19: A Japanese multicenter inpatient database study.. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2024. DOI: 10.1016/j.jiac.2024.09.020.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.